ArticleObesity science & practice2019
Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study.
Article in Obesity science & practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Pharmacokinetics and Food Effect of HDM1002, a Novel Oral Small-Molecule GLP-1 Receptor Agonist, in Healthy Chinese Volunteers: A Bioequivalence Study.Diabetes, obesity & metabolism · 2026Trial
- Efficacy and safety of beinaglutide with continuous subcutaneous infusion in newly diagnosed patients with type 2 diabetes: a randomized, control, open-labeled clinical trial.Journal of endocrinological investigation · 2025Trial
- Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.Diabetes, obesity & metabolism · 2025Trial
- Effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies in patients with type 2 diabetes: a randomized clinical trial.Frontiers in endocrinology · 2023Trial
- Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial.Frontiers in endocrinology · 2023Trial
- A Novel Multiphase Modified Ketogenic Diet: An Effective and Safe Tool for Weight Loss in Chinese Obese Patients.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Trial
- The effect of beinaglutide on visceral fat and body weight in obese type 2 diabetic patients.Archives of medical science : AMS · 2026Article
- Effect of Polyethylene Glycol Loxenatide Treatment on Body Weight in Patients With Type 2 Diabetes With Different Body Mass Index: A Retrospective Real-World Study.International journal of endocrinology · 2026Article
- Outcomes of Beinaglutide on Weight Loss in Patients With Diabetes or Obesity: A Systematic Review and Meta-Analysis.Cureus · 2025Review
- Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential.Toxicology reports · 2025Review
- Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis.World journal of diabetes · 2025Article
- The effect of beinaglutide as an glucagon-like peptide-1 receptor agonists on cardiometabolic factors: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2025Article
- Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.Journal of obesity · 2025Review
- A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways.Frontiers in endocrinology · 2025Review
- Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration.Pharmaceutics · 2024Review
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024 · on this mapReview
- Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.Pharmaceuticals (Basel, Switzerland) · 2024Article
- The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists.Current medicinal chemistry · 2024Review
- Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.Frontiers in endocrinology · 2024Article
- Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe purpose of this study was to examine the effectiveness of beinaglutide on body weight, glycated haemoglobin (HbA MATERIALS AND
methodsThis was a multicentre, observational, retrospective, open-label study conducted in China. Data were collected from T2DM patients who started treatment with beinaglutide between 2017 and 2018.
resultsA total of 314 patients were included in the study. After 3 months of treatment with beinaglutide, there were significant reductions in body weight (-10.05 kg [95% confidence interval -9.29 to -10.80]), HbA
conclusionsThese observational results confirmed the benefits of beinaglutide in weight loss and glycaemic control and support the use of beinaglutide as an effective treatment for T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.